Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oraloncology.2019.02.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.
ESMO Open
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.
Background: The HER2DX assay predicts long-term prognosis and pathologic complete response (pCR) in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving neoadjuvant systemic therapy but has not been evaluated in inflammatory breast cancer (IBC).
Patients And Methods: HER2DX was analyzed in baseline biopsy tissues from 23 patients with stage III HER2-positive IBC on a phase II trial (NCT01796197) treated with neoadjuvant trastuzumab, pertuzumab, and paclitaxel (THP). To assess the assay's predictive accuracy for pCR in IBC, clinical-pathological features and outcomes from this IBC cohort were compared with 156 patients with stage III HER2-positive non-IBC from four different cohorts.
Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.
J Cancer Res Ther
December 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China.
Article Synopsis
- The study examines the effects of a combination therapy (apatinib and trastuzumab-based chemotherapy) on patients with primary trastuzumab resistance (PTR) in HER2-positive breast cancer.
- A total of 20 PTR patients were treated, showing a clinical benefit rate of 55%, though no complete responses were observed, and median progression-free survival was 5.7 months.
- While the treatment had manageable side effects, further research is recommended to better identify which PTR patients could potentially benefit from this therapy.
Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features.
J Transl Med
January 2025
Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
Background: First-line treatment for advanced gastric adenocarcinoma (GAC) with human epidermal growth factor receptor 2 (HER2) is trastuzumab combined with chemotherapy. In clinical practice, HER2 positivity is identified through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), whereas deep learning (DL) can predict HER2 status based on tumor histopathological features. However, it remains uncertain whether these deep learning-derived features can predict the efficacy of anti-HER2 therapy.
View Article and Find Full Text PDFImprovement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent.
Ann Nucl Med
November 2024
Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Objective: Monoclonal antibody (mAb)-based radioimmunoconjugates (RICs) exhibit marked tumor uptake in cancer imaging and therapy, although their high blood retention has limited the development of RICs. In our previous study, a trifunctional chelating agent with a cationic poly(ethyleneimine) (PEI) structure of tetraethylenepentamine (PEI4), maleimide-DOTA-PEI4 (MDI4), improved the tumor-to-blood ratio of RICs by increasing tumor retention compared with a conventional bifunctional chelating agent. In this study, we developed a novel chelating agent composed of a maleimide moiety, DOTA derivative, and two PEI4 structures as a PEI4-2 unit, maleimide-DOTA-PEI4-2 (MDI4-2), a design for a highly cationized chelating agent to synthesize RICs.
View Article and Find Full Text PDFPrognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials.
Ann Surg Oncol
February 2025
Department of Breast Surgery, General Surgery, Clinical Research Center for Breast Cancer in Hunan Province, National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Xiangya Hospital, Central South University, Xiangya, China.
Purpose: The systemic immune-inflammation index (SII) is a hematological marker that reflects the immune status of the body. This study was designed to evaluate the prognostic significance of the baseline SII in HER2-positive metastatic breast cancer (MBC) patients receiving chemotherapy plus trastuzumab without or with pertuzumab.
Methods: Data were collected from 774 patients from the CLEOPATRA trial, 196 patients from the H0648G trial, and 229 patients from six clinical centers in China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!